Skip to main content
. Author manuscript; available in PMC: 2021 Jan 15.
Published in final edited form as: AAPS J. 2020 Jan 15;22(2):29. doi: 10.1208/s12248-019-0391-1

Fig.6.

Fig.6.

Interplay of dose and receptor density. A Bound concentration of T-DM1with coadministration with trastuzumab (ratios trastuzumab to T-DM1 from 0:1 to 12:1) for tumors with different receptor densities. The Thiele modulus (calculated using total antibody dose) shows saturation when the value is less than ~ 0.2. b Average tumor volume at 30 days for different treatment regimens and tumors with different average receptor densities. The optimal carrier dose is dependent on receptor expression with higher trastuzumab doses needed for higher receptor expression. With the potency of this ADC, no efficacy is seen below 50,000 HER2/cell (Fig S4)